Ipsen’s Partner Roche Announces that Taspoglutide Meets its Primary…
Posted by: DrugsNews on: 19 Dec, 2009
Ipsen’s Partner Roche Announces that Taspoglutide Meets its Primary…
Dec 17, 2009 – Regulatory News: Ipsen , an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 analogue based on a human …
Read more about Ipsen’s Partner Roche Announces that Taspoglutide Meets its Primary…
Get pricing and discount on generic medicines for Diabetes from www.roxpharmacy.com
| Indian Pharmacy! Looking for Generic Medications? Quality Drugs at affordable prices! Reliable Indian Pharmacy www.IndianPharmacy.org |
#1 Canadian Pharmacy Online! The Lowest Prices from Canadian Drugstore! Various payments, secure shopping, worldwide shipping! www.CanadianPharmacyLtd.org |
What are the Drugs-Review websites?
The Drugs-Review websites are NOT but will be your number one stop for all the latest news, comment and pharmaceutical industry information.
Related posts:
- Ipsen’s Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint In The First Phase III Clinical Trial
- Ipsen?s partner Roche announces that Taspoglutide meets its primary endpoints in two further head-to-head phase III studies with insulin glargine (Lantus) and versus placebo in patients with high body mass index (BMI)
- Ipsen’s Partner Roche Announces That Taspoglutide Meets Its Primary Endpoints in Head-to-Head Study with Sitagliptin (Januvia) and versus Placebo
